New hope to keep aggressive cancer at bay after initial treatment
NCT ID NCT07493109
Summary
This study is testing whether a drug called chidamide can help prevent a type of aggressive blood cancer (DLBCL) from coming back in patients who also have hepatitis B. It is for people whose cancer initially responded well to standard chemotherapy. The goal is to see if taking chidamide after chemo keeps patients in remission longer compared to just watching and waiting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Bethune Hospital of Jilin University
RECRUITINGChangchun, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.